Register for our free email digests:
Division of Newron Pharmaceuticals SPA
Latest From Taiho Pharmaceutical Co. Ltd.
Chi-Med's China-focused strategy is paying off with positive Phase III top-line results for its home-grown VEGF inhibitor fruquintinib, keeping it on track to for a filing this year. But competition looms.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Keytruda has been approved in Japan for lung cancer, including first-line use, in a batch of new regulatory clearances that also include the country's first prescription drug for irritable bowel syndrome with constipation.
Regulatory authorities in Japan have put back the granting of a reimbursement price to Keytruda under the national health insurance system amid rising worries over the cost of new cancer immunotherapies, delaying the launch of the product for now.
- Large Molecule
- Therapeutic Areas
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Newron Pharmaceuticals SPA
- Senior Management
Ulf Ljungberg, PhD, Pres. & CEO
Henrik Resmark, CFO
Anders Haegerstrand, MD, PhD, CSO
- Contact Info
Phone: (46) (0)8 786 0900
Fiskartorpsvägen 15 A-D
Stockholm, SE-114 33
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.